Liquid biopsy tests grow in use and show promise in cancer detection, but experts say more trials are needed on the clinical benefit of ctDNA testing.
In this week's edition of Adam's Biotech Scorecard, Adam also takes on the PD(L)1-VEGF antibody cancer treatments garnering so much attention.
The PTO decision to review the patent “likely reduces the probability” that Halozyme will prevail, said Wells Fargo analyst Mohit Bansal.
The benefit from the study’s exercise program was about as large as what researchers might expect from a new drug, experts said.
